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Objectives: The digitalisation of sexual and reproductive health (SRH) services offer valuable 
opportunities to deliver contraceptive pills and Chlamydia treatment by post. We aimed to 
examine the acceptability of remote prescribing and “medication-by-post” in SRH.
Study design: An online survey assessing attitudes towards remote management was 
distributed in three UK SRH clinics and via an integrated sexually transmitted infection (STI) 
postal self-sampling service. Logistic regressions were performed to identify potential 
correlates.  
Results: There were 1281 participants (74% female and 49% <25 years old). Eight per cent 
reported having received medication via post and 83% were willing to receive Chlamydia 
treatment and contraceptive pills by post. Lower acceptability was observed among 
participants who were: >45 years old OR:0.43(0.23-0.81), screened for STIs less than once 
annually OR:0.63(0.42-0.93), concerned about confidentiality OR:0.21(0.90-0.50), concerned 
about absence during delivery OR:0.09(0.02-0.32), unwilling to provide blood pressure 
readings OR:0.22(0.04-0.97). Higher acceptability was observed among participants who 
reported: previously receiving medication by post OR:4.63(1.44-14.8), preference for home 
delivery over clinic collection OR:24.1(11.1-51.9), preference for home STI testing 
OR:10.3(6.16-17.4), ability to communicate with health advisors OR:4.01(1.03-15.6), and 
willingness to: register their real name OR:3.09(1.43-10.6), complete online health 
questionnaires OR:3.09(1.43-10.6), and use generic contraceptive pills OR:2.88(1.21-6.83).
Conclusion: Postal treatment and entering information online to allow remote prescribing 
were acceptable methods for SRH services and should be considered alongside medication 
collection in pharmacies. These methods could be particularly useful for patients facing 
barriers in accessing SRH. The cost-effectiveness and implementation of these novel methods 
of service delivery should be further investigated.  
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Key messages
• The majority (83%) of sexual health service users would be willing to receive 
contraceptive pills and Chlamydia treatment via post. While 1 in 5 would prefer to 
receive medication directly from the doctor. 
• Remote prescribing, postal delivery (medication-by-post) and click-and-collect 
services are highly acceptable in sexual and reproductive health
• However, those above the age of 45 years, first time or infrequent service attenders, 
those who do not use online health services and are concerned about their 
confidentiality were less likely to accept remote prescribing. 
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Introduction
Every day, about one million people acquire a sexually transmitted infection (STI), 
worldwide.[1] In England, around 450,000 new STIs are diagnosed every year and people 
aged 16-24-year-old account for 50% of new diagnoses.[2] The estimated costs of STI 
treatments equate to £620 million per year.[3] Gay, bisexual and other men who have sex 
with men (MSM) as well as Black Asian and minority ethnic (BAME) individuals are the 
most affected. [2] 
Chlamydia trachomatis is the most common bacterial STI in North America and 
Europe.[4] If left untreated, Chlamydia can cause pelvic inflammatory disease, tubal 
infertility and ectopic pregnancy in women, as well as epididymal-orchitis in men and less 
frequently sexually acquired reactive arthritis in both genders.[5] The UK introduced The 
National Chlamydia Screening Programme (NCSP) in 2003 to improve detection, decrease 
transmission rates, and reduce the associated morbidities.[6] There has been a significant shift 
towards providing online sexual and reproductive health services (SRHS), including the 
utilisation of self-sampling/-testing kits, which is particularly pertinent to 15-24-year-old 
women in whom Chlamydia is most prevalent.[7] As STIs continues to be a major public 
health concern, policy-makers emphasise the need for optimal and cost-effective methods for 
increasing screening and treatment uptake.[8] Young women are also at an increased risk of 
unplanned pregnancies, thus the provision of contraception services is a cost-effective public 
health intervention. In the UK, 45% of pregnancies were unplanned in women aged 16-19.[9] 
As a significant proportion of women face barriers to healthcare access, individual, social and 
service-delivery considerations need to be addressed to reduce these barriers and increase the 
cost-effectiveness and efficiency of SRHS.  
Digitalisation offers solutions to service delivery aiding standard care. It has been 
driven by the need to manage demand in an increasing austere financial environment, to 
increase access, equity and reduce the burden on overstretched face-to-face services in what 
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is hoped to be a cost-effective manner. Research has demonstrated that women benefit from 
digital sex education and counselling around contraceptive choices and STI screening.[10-
11]. Online services are feasible, safe and effective in the management of patients with 
Chlamydia and other STIs.[12] The proportion of Chlamydia tests that are provided via 
online postal self-sampling services has rapidly increased, with 17% of all chlamydia tests in 
15 to 24-year-olds in 2018 being accessed online in the UK.[2] This has also been accelerated 
during the COVID-19 pandemic, where serviced had to rapidly switch to online delivery. 
Users express positive attitudes to online services that are convenient, fast, secure and linked 
with pharmacies or helplines.[13] Pathway frameworks offer a comprehensive structure of e-
health services in sexual and reproductive medicine as a powerful tool in public health and 
clinical management.[14] Standardised digital history taking tools, which can be used in both 
face-to-face and remote clinical settings, have the potential to improve the quality of drug 
prescription and patient safety if users are willing to provide the necessary clinical 
information. 
Solent SRHS have provided online postal self-sampling to the Hampshire (UK) 
community since 2015. The service considered remote consultations and provision of 
contraception and Chlamydia treatment via postal delivery. Before introducing these services, 
the acceptability of remote management in the population needs to be established to identify 
barriers to effective implementation. We aimed to assess the acceptability and preferences for 
remote prescribing and delivery of Chlamydia treatment and contraception by post. 
Methods
Design
This was an exploratory, cross-sectional survey focusing on service users’ willingness 
to input clinical information online and receive Chlamydia treatment and contraceptive pills 
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delivered by post. The survey was approved as a service evaluation & development by Solent 
NHS Trust Clinical Governance (ref:SE-271).
Participants and data collection
Between May and August 2018, we conducted a cross-sectional survey exploring 
potential “mediation-by-post” services for Solent NHS Trust SRHS. We recruited 
participants above the age of 16 years accessing services within Hampshire, UK. The survey 
was designed after consultations with service users about the development of online services. 
Views were gathered to formulate this questionnaire available in both pencil-and-paper and 
digital formats. Eight hundred paper surveys were distributed in three sexual health clinics. 
Service users were encouraged to complete the anonymous questionnaire while registering 
for their clinical appointment, with completion indicating their consent. Completed surveys 
were returned to the reception in an envelope and placed in a secure location. Additional 600 
surveys were sent to those who requested an online STI self-sampling kit via SRHS website: 
www.letstalkabout.nhs.uk. They were then asked to return it in an envelope to the laboratory 
which processed the samples. Also, a web link to an online survey was advertised on the 
SRHS website and Twitter for additional responses. We were unable to calculate the overall 
response rate as there was no record of how many questionnaires were accessed online, 
nevertheless, 866 paper surveys were completed.   
Measurement
The survey consisted of 32 questions (see supplementary appendix 1), including 
demographic variables such as age, gender identity, ethnicity, sexual orientation, education, 
whether participants were registered with a General Practitioner and any past STI diagnoses. 
Participants were asked about their preferred method for, and frequency of, STI screening 
and whether they had previously collected any medication via post or at a pharmacy with 
options ‘Delivered at home’, ‘Given by a doctor” or “Collected at my pharmacy”. 
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Two outcome variables measured the acceptability of postal treatment services: i) the 
willingness to receive Chlamydia treatment (antibiotics) by post and ii) the willingness to 
receive contraceptive pills by post, both with options “Yes”, “No” and “Not sure” (“Would 
you be willing to receive medication (antibiotic) to treat chlamydia by post?”). Other 
questions assessed the most preferred methods for receiving medication and the concerns 
about confidentiality in receiving them by post. The acceptability of remote prescribing was 
assessed by asking about willingness: to be contacted by a health advisor, to completing an 
online questionnaire, to disclosing pre-existing medical conditions, to providing blood 
pressure reading, to accepting generic (non-branded) medication and to registering their real 
name and contact details before the order being finalised. Specific preferences for a tracked 
delivery of the medication, a mobile phone text message with the status of the order and the 
need to discuss the side-effects and dosage with a pharmacist were assessed to inform the 
development of the service. Also, an expected arrival delivery time and the time to contact 
the clinic in case of misplaced delivery were assessed. The questions related to the 
contraceptive pill were only directed to women. 
Patient and public involvement
Patients were not directly involved in the design, recruitment and the conduct of the survey. 
Posters were disseminated in the waiting areas outlining the results of the study. 
Data analysis
The variables were either categorical or ordinal. Descriptive statistics were performed 
to identify the percentage of responses using IBM SPSS software version 24. All variables 
were then dichotomised (i.e. ‘yes’ and ‘no/unsure’; see Table 2). Twenty-one simple logistic 
regressions with single categorical predictor were performed to identify potential correlates 
of acceptability of the two outcome variables and calculate odds ratios and 95% confidence 
intervals to determine their magnitude. No modelling was used to perform regressions due to 
the explorative nature of the analysis.  
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Results
In total, 1281 service users completed the survey, with about a half (49%) under the 
age of 25 years (Table 1). The majority (74%) identified as female, White (91%), 
heterosexual or straight (86%), and having a college or university education (78%). Almost 
all (95%) were registered with GP services and 40% reported being diagnosed with an STI in 
the past. While half of the sample reported STI screening once per year or more often, for 
20% the survey testing was the first time they had been screened. Nearly half (48%) stated 
that remote STI self-sampling, using an online testing kit, was their preferred method of STI 
screening.  
While the majority (87%) had collected medication at a pharmacy, only 8% reported 
ever receiving medication by post. In general, most participants preferred to either be given 
the medication by a doctor (20%) or collect it at a pharmacy (34%). However, in terms of 
receiving Chlamydia treatment and contraceptive pills, many (45%) chose home delivery as 
their preferred method. When asked directly, around 83% of participants were willing to 
receive antibiotics and contraceptive pills by post. 
The assessment of preferences for remote prescribing showed that most participants 
reported their willingness to complete an online questionnaire (78%), register their real name 
and contact details (85%), disclose pre-existing conditions (89%), and speak to a health 
advisor on the phone (85%) before the finalisation of the medication order. Only 27% 
reported a preference for a consultation about dosage and side-effects with a pharmacist. 
Regarding contraception for women, 81% would be willing to provide blood pressure 
readings and 67% would accept receiving a generic version of the contraceptive pill.
The assessment of preferences for the “medication by post” method showed that most 
participants (76%) were not concerned about confidentiality, but 44% would be concerned 
about the medication delivery if they were away from home. Only 35% endorsed a preference 
for signed tracked delivery of medication. The majority (83%) would prefer to receive a 
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mobile phone update about their delivery and most participants (86%) thought that delivery 
within 3 working days was appropriate, although a substantial proportion indicated “next day 
delivery” as their preferred option for Chlamydia treatment (43%) and contraception (37%). 
While 48% of the sample would wait 2-3 days to contact the clinic if the medication was not 
delivered, about 36% would wait only 1 day. Sexual health clinics were perceived as the 
preferred source of advice on the medication by post.   
  The highest willingness (99%) of using remote services for chlamydia treatment was 
observed amongst participants who showed strong preferences for ‘home delivery methods’ 
of medication; the lowest willingness (41%) was reported by the participants who would not 
register their real name for the medication order. Lower acceptability of Chlamydia treatment 
by post was observed amongst participants who were: above the age of 45 years, screened for 
STI less than once a year, concerned about their confidentiality, concerned about the delivery 
during their absence, and those not willing to provide their blood pressure readings. Higher 
acceptability was observed amongst participants who had received medication by post in the 
past, preferred the home delivery method for medication, preferred online/home testing for 
STIs, were willing to speak with a health advisor, register their real name, complete online 
health questionnaires, and use generic medication.
The highest willingness (97%) of using remote services for contraceptive pills was 
observed amongst women who were willing to use generic, non-branded versions of the 
medication and the lowest willingness (47%) was seen amongst the participants who would 
prefer not to register their real name for the medication order. Lower acceptability of 
receiving contraceptive pills by post was observed amongst participants who were: above the 
age of 45 years and those who expressed a preference for a consultation with a pharmacist to 
discuss side-effects and dosage. Higher acceptability was reported by women who had 
collected medication at a pharmacy in the past and who were willing to complete an online 
questionnaire about their health before ordering medication.
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Discussion
To our knowledge, this is the first study exploring the acceptability and user 
preferences for remote prescribing and postal treatment for chlamydia treatment and 
contraception provision. The findings indicate that most participants would agree to provide 
the necessary information for remote prescribing such as real name, medical and drug/allergy 
history and blood pressure readings.[15-16] Although approximately only 1 in 12 participants 
had previously received medication in the post, the majority reported “medication by post” or 
“click and collect” as their preferred delivery methods. This suggests that a significant 
proportion of service users would be receptive to remote antibiotic treatment and 
contraception services, as the preferences overlap with acceptability, indicating the 
willingness to receive medication away from the clinic. Most participants were willing to 
receive generic drugs and would expect delivery within three working days or in the case of 
Chlamydia treatment, next day delivery. Sexual health clinics were the preferred source of 
information about “medication by post”.
Previous studies have demonstrated the value of assessing acceptability and 
motivations for digital services. One study indicated mixed attitudes towards remote 
prescribing services amongst health professionals, with perceived usefulness, ease of use and 
perceived risk of error in prescribing associated with acceptability.[17] A small study of 
medication by post in Malaysia showed that services users were unaware of this method of 
delivery and only a half showed interest in the service, with the majority reporting concerns 
with a potential missed delivery.[18] In the present study, about 20% of participants were not 
willing to provide via an online questionnaire the information necessary to allow safe 
prescribing,=. Hence, users’ concerns should be explored in more detail in subsequent 
research to identify common barriers and design user-centred digital service for all patients 
and identify those who find digital services less suitable. Although telemedicine offers 
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valuable opportunities, there is a risk of widening health inequalities due to access to digital 
technologies.[19] Thus, service users who are not capable or unwilling to use e-prescribing 
due to digital literacy, access to technology or personal preferences should have access to 
alternative pathways of care.
This study achieved a large sample size and provides novel knowledge about online 
services. However, there are several limitations as it was exploratory and not designed to test 
prespecified hypotheses. The participants were recruited within one NHS Trust in Hampshire 
and their responses may not be representative of service users in other regions, especially in 
big cities, and individuals that are ‘seldom heard’ or hard-to-engage. Due to various sources 
of recruitment, we were uncertain about the refusal rate and how that affected the 
representativeness of the sample. Also, the survey was conducted before the coronavirus 
outbreak and patients’ views on remote prescribing and postal treatment might be different if 
assessed now. The novel coronavirus SARS-COV-2 outbreak in 2020 transferred the majority 
of SRHS either to phone or online assessments, as face-to-face healthcare was dramatically 
reduced, due to social distancing measures and staff illness or redeployment. Remote 
management using phone assessments and online services has allowed service providers to 
continue, including diagnosis and management of sexual health conditions with remote 
prescribing and postal treatment or “click-and-collect”. These developments mean that the 
current findings are of particular importance by providing insight into individuals’ 
preferences before service changes being implemented and will inform future service 
development as we transition from lockdown to a post-SARS-COV-2 time.
In conclusion, as a majority of service users in this study were receptive to these 
methods of delivery, remote prescribing and postal delivery of treatment for uncomplicated 
chlamydia and contraception should be considered as part of SRHS. Nevertheless, such a 
service needs to be closely monitored to identify any potential missed delivery, medication 
non-adherence, or misuse. Further research needs to explore health professionals’ and users’ 
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concerns as well as individual barriers to design the most acceptable, effective, and equitable 
digital SRH services supporting patients with their treatment and prophylaxis. 
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Table 1. Sample characteristics and preferences for e-prescribing (N=1281)
Variable Total number 
(%)




   <18
   18-24
   25-34
   35-44
   45-54
   55-64
   Over 65
Gender
   Male
   Female
   Non-binary
   Other
Ethnicity
   White
   Black African
   Black Caribbean
   Asian
   Mixed-race
   Other
Sexual orientation
   Heterosexual or Straight
   Gay or Lesbian
   Bisexual
   Prefer not say and other
Education
   No formal education
   Primary school
   High school
   Collage
   University degree
   Other
Registered with GP
   Yes
   No/not sure
Past STI diagnosis
   Yes
   No
   Not sure
The frequency of STI screening
   First time
   Once every few years
   Once a year
   Several times a year
The preferred method of STI screening
   Online (home) testing
   At a sexual health clinic 
   At GP surgery
   Other
Variables related to medication delivery
Ever collected medication at the pharmacy
   Yes
   No/not sure
Ever received medication via post
   Yes
   No/not sure
Preference for receiving medication (general)
   Delivered to home
   Given by a doctor
   Collected at pharmacy
   Other
Preference for receiving chlamydia treatment
   Delivered to home
   Given by a doctor at the clinic
   Collected at pharmacy
   Other
Preference for receiving contraceptive pills
   Delivered to home
   Given by a doctor at the clinic
   Collected at pharmacy

























































Preferences for remote prescribing and postal 
treatment
Willingness to receive antibiotic by post
   Yes
   No/not sure
Willingness to receive contraceptive pills by post
   Yes
   No/not sure
Willingness to provide blood pressure reading
   Yes
   No/not sure
Willingness to receive generic contraceptive pills 
   Yes
   No/not sure
Concerned about confidentiality using post delivery
   Yes
   No/unsure
Concern about delivery if absent at home
   Yes
   No/unsure 
Willingness to speak with health advisor via phone prior 
to finalise medication order
   Yes
   No/unsure
Willingness to disclose pre-existing conditions
   Yes
   No/unsure
Willingness to register a real name for the order
   Yes
   No/not sure
Willingness to fill in an online questionnaire about health 
prior to medication order
   Yes
   No/not sure
Preference for signed tracked delivery 
   Yes
   No/not sure
Preference for a consultation with a pharmacist to discuss 
side-effects and dosage 
   Yes
   No/not sure
Preference for mobile phone updates about the delivery 
status
   Yes
   No/not sure
Preferred waiting time for antibiotic to be delivered
   Next day delivery 
   Within 3 working days
   Within 5 working days
   Within 7 working days
Preferred waiting time for contraceptive pills to be 
delivered
   Next day delivery 
   Within 3 working days
   Within 5 working days
   Within 7 working days
Optimal waiting time to contact the clinic in case the 
delivery is misplaced
   1 day
   2-3 days
   4-7 days
   Over a week
A preferred source of advice on the medication delivered 
by post
   GP
   Sexual health clinic
   Pharmacy











































GP -General Practitioner, STI – sexually transmitted infection
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Table 2. Correlates of the willingness to receive medication by post
Variable (%) of those ‘willing’ to receive 
chlamydia treatment by post with 
Odds ratio [95% Confidence 
intervals]
(%) of those ‘willing’ to receive 
contraceptive pills by post with 
Odds ratio [95% Confidence 
intervals]
Age
   Under 45 years
   45+
Gender
   Male
   Female
Ethnicity
   White
   Ethnic minority (non-white)
Sexual orientation
   Heterosexual
   Sexual minority
Education 
   High school or below
   College and university degree
Registered with a GP
   Yes
   No
Past STI infection
   Yes
   No
Ever collected medication at the pharmacy
   Yes
   No
Ever received medication via post
   Yes
   No
The frequency of STI screening
   First time or less than once a year
   Once a year or more often
The preferred method of STI screening
   Online (home) testing
   In-clinic (GP or sexual health)
Preference for receiving medication (general)
   Delivered to home
   Collected from a pharmacy or a doctor
Concerned about confidentiality   
   Yes
   No
Concern about delivery if absent at home
   Yes
   No
Willingness to speak with health advisor via phone 
prior to finalise medication order
   Yes
   No
Willingness to disclose pre-existing conditions
   Yes
   No
Willingness to register a real name for the order
   Yes
   No
Willingness to fill in an online questionnaire about 
health prior to order
   Yes
   No
Willingness to provide blood pressure reading
   Yes
   No
Willingness to receive generic (non-branded) 
medication 
   Yes
   No
Preference for a consultation with a pharmacist to 
discuss side-effects and dosage 
   Yes
   No
(88.0)    1.00 - ref
(76.3)    0.43 [0.23-0.81]*
(81.1)    1.00 - ref
(88.8)    1.48 [0.96-2.29]
(87.2)    1.00 - ref
(84.1)    0.78 [0.41-1.49]
(87.3)    1.00 - ref
(88.1)    1.09 [0.60-2.00]
(89.1)    1.00 - ref
(86.6)    0.73 [0.42-1.26]
(87.2)    1.00 - ref
(77.4)    0.53 [0.19-1.48]
(88.4)    1.00 - ref
(86.1)    0.75 [0.50-1.13]
(87.6)    1.37 [0.84-2.22]
(83.7)    1.00 - ref
(96.7)    4.63 [1.44-14.8]*
(86.2)    1.00 - ref
(83.1)    0.63 [0.42-0.93]*
(91.0)    1.00 - ref
(97.1)    10.3 [6.16-17.4]*
(76.7)    1.00 - ref
(98.8)    24.1 [11.1-51.9]*
(76.7)    1.00 - ref
(60.6)    0.21 [0.90-0.50]*
(94.6)    1.00 - ref
(75.2)    0.09 [0.02-0.32]*
(95.6)    1.00 - ref
(91.9)    4.01 [1.03-15.6]*
(54.5)    1.00 - ref
(91.0)    2.87 [0.79-10.4]
(51.4)    1.00 - ref
(91.9)    5.65 [1.76-18.1]*
(41.2)    1.00 - ref
(94.5)    3.09 [1.43-10.6]*
(54.1)    1.00 - ref
(89.7)    1.00 - ref
(80.1)    0.20 [0.04-0.97]*
(93.9)    2.88 [1.21-6.83]*
(71.9)    1.00 - ref
(78.2)    0.52 [0.23-1.16]
(90.3)    1.00 - ref
(84.9)    1.00 - ref
(56.8)    0.19 [0.09-0.41]*   
0
(83.7)    1.00 - ref
(78.6)    0.87 [0.42-1.80]
(83.9)    1.00 - ref
(78.2)    0.77 [0.38-1.58]
(83.9)    1.26 [0.75-2.10]
(84.0)    1.00 - ref
(83.3)    1.00 - ref
(69.6)    0.57 [0.15-2.06]
(85.9)    1.40 [093-2.11]
(82.5)    1.00 - ref
(84.3)    2.04 [1.20-3.47]*
(75.8)    1.00 - ref
(85.3)    1.56 [0.66-3.73]
(83.0)    1.00 - ref
(80.7)    0.77 [0.51-1.16]
(86.3)    1.00 - ref
(88.1)    1.63 [1.05-2.55]
(78.6)    1.00 - ref  
(89.8)    2.30 [1.44-2.55
(77.7)    1.00 - ref
(67.8)    0.61 [0.25-1.44]
(88.4)    1.00 - ref
(78.3)    0.83 [0.36-1.89]
(87.3)    1.00 - ref
(85.5)    1.68 [0.49-5.74]
(60.6)    1.00 - ref
(85.9)    1.00 - ref  
(55.3)    0.35 [0.13-2.05]
(87.7)    2.00 [0.58-6.86]
(47.1)    1.00 - ref
(88.8)    3.67 [1.45-9.27]*
(60.9)    1.00 - ref
(82.2)    2.08 [0.83-5.22]
(56.2)    1.00 - ref
(97.5)    35.8 [15.8-81.3]
(44.1)    1.00 - ref
(75.0)    0.34 [0.16-0.73]*
(86.1)    1.00 - ref
*p<0.05, GP -General Practitioner, STI – sexually transmitted infection
